文献速递胸部CT

COVID-19 后长达 3 年的长期肺功能与影像学异常:系统评价与 Meta 分析

Long-Term Pulmonary Function and Radiologic Abnormalities Up to 3 Years After COVID-19: A Systematic Review and Meta-Analysis.
PubMed 文献 · Korean J Radiol · 2026-01-01

该系统评价与 Meta 分析纳入 152 项研究(共 25,766 例,平均年龄 56.7±13.2 岁,男性 14,999 例),评估 COVID-19 后 6 至 36 个月的肺功能与胸部 CT 表现。DLCO 受损从 6 个月的 42% 降至 36 个月的 35%(P=0.008),FVC 受损随时间下降,磨玻璃影从 32% 降至 20%(P=0.01),而纤维化持续在 27%-47% 且无显著变化(P=0.28)。

要点

  • DLCO 受损是最常见的异常,从 6 个月 42% 降至 36 个月 35%(P=0.008)。
  • 胸部 CT 上磨玻璃影从 6 个月 32% 降至 36 个月 20%(P=0.01)。
  • 纤维化持续在 27%-47% 且无显著变化(P=0.28),呈稳定但非进展模式。

核心结论

  • DLCO、FVC 和磨玻璃影在 COVID-19 后 36 个月内逐渐改善,但超过三分之一的患者仍存在 DLCO 降低;纤维化持续存在,3 年内消退证据有限,提示稳定但非进展的模式。

研究设计与样本

  • 系统评价与 Meta 分析,检索 PubMed 和 EMBASE 2020 年 1 月至 2024 年 6 月发表的报告 COVID-19 后 ≥6 个月至 36 个月肺功能和/或胸部 CT 结局的研究,共纳入 152 项研究(n=25,766;平均年龄 56.7±13.2 岁;男性 14,999 例),其中 133 项报告肺功能结局、80 项报告 CT 表现。

关键影像表现/征象

  • 胸部 CT 上无相关发现的患者比例稳定在 30%-40%(P=0.14)。
  • 磨玻璃影的患病率从 6 个月的 32% 降至 36 个月的 20%(P=0.01)。
  • 纤维化的患病率持续在 27%-47% 且无显著变化(P=0.28)。

诊断标准与关键数值

  • DLCO 受损患病率从 6 个月的 42% 降至 36 个月的 35%(P=0.008),同时 DLCO 占预计值百分比相应增加。
  • FVC 受损患病率随时间下降,同时 FVC 占预计值百分比增加。
  • 基于疾病严重程度的亚组分析显示低严重度和高严重度队列中时间趋势相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To systematically evaluate the long-term trajectory of pulmonary function test (PFT) and CT findings in COVID-19 survivors.

MATERIALS AND METHODS: A systematic literature search of PubMed and EMBASE was performed to identify studies published from January 2020 to June 2024 reporting PFT and/or chest CT outcomes at ≥6 months post-COVID-19, up to 36 months. The reference lists of relevant articles were also manually reviewed. Two investigators independently extracted study characteristics, patient demographics, and PFT and CT outcomes at prespecified follow-up intervals (6, 12, 24, and 36 months). Multivariate meta-analyses were conducted to evaluate temporal trends in lung function and radiological abnormalities. Sensitivity analyses, including stratification by disease severity and pooled analyses of studies with multiple follow-up time points, were performed to confirm the robustness of the findings.

RESULTS: In total, 152 studies (n = 25,766; mean age, 56.7 ± 13.2 years; 14,999 men) were included: 133 reporting PFT outcomes and 80 reporting CT findings. Diffusion capacity (DLCO) impairment was the most common abnormality, showing gradual improvement from 42% at 6 months to 35% at 36 months (P = 0.008) with a corresponding increase in the % predicted DLCO. Similarly, the prevalence of forced vital capacity (FVC) impairment decreased over time, accompanied by an increase in the % predicted FVC. On chest CT, the proportion of patients with no relevant findings remained stable at 30%-40% (P = 0.14). The prevalence of ground-glass opacities (GGO) decreased from 32% at 6 months to 20% at 36 months (P = 0.01), while that of fibrosis persisted at 27%-47% without a significant change (P = 0.28). Subgroup analysis based on disease severity revealed similar temporal trends in both low-severity and high-severity cohorts.

CONCLUSION: DLCO, FVC, and GGO findings improved gradually up to 36 months post-COVID-19; however, over one-third of the patients continued to exhibit reduced DLCO. Fibrosis persists with limited evidence of resolution over a 3-year period, suggesting a stable but nonprogressive pattern.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Song J, Lee JH, Park H, et al. Long-Term Pulmonary Function and Radiologic Abnormalities Up to 3 Years After COVID-19: A Systematic Review and Meta-Analysis. Korean J Radiol. 2026. PMID: 41592552. doi:10.3348/kjr.2025.1272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。